Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782821 · ClinicalTrials.gov registry record · Phase 4
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00782821 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 40 participants.
The verdict
NCT00782821, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with Prograf®, Cellcept® and corticosteroid therapy.
Interventions
- DRUG Velcade
- DRUG Rituxan
- DRUG Rabbit Antithymocyte Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782821
The ClinicalTrials.gov registry entry for NCT00782821 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Velcade is the first listed.
NCT00782821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782821 about?
NCT00782821 is a clinical study titled "Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients". The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with Prograf®, Cellcept® and corticosteroid therapy.
What is the current status of trial NCT00782821?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00782821?
The interventions under investigation include: Velcade (DRUG), Rituxan (DRUG), Rabbit Antithymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00782821?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.